Medical Device | January 10, 2024
Bruker acquires Tornado Spectral Systems to expand biopharma PAT product portfolio
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
Comprehensive clinical development programs being initiated for each investigational candidate
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Sirius JV will be owned 51% by Sirius and 49% by Adani
Subscribe To Our Newsletter & Stay Updated
